

Metoprolol is Beneficial for Patients having Heart Failure with Preserved Ejection Fraction.

Mittal N, et al. Perspectives in Clinical Research. 2017; 8(3): 124-131.

- There is a lack of evidence-based therapies for the treatment of heart failure (HF) with preserved ejection fraction (HFpEF). Beta blockers may provide some benefit in HFpEF due to their proven role in HF with reduced ejection fraction.
- In a double-blind, 14-week pilot study, metoprolol succinate improved the grading of HF (New York Heart Association class), echocardiographic parameters, exercise capacity and quality of life (QoL) parameters in patients with HFpEF.
- No serious adverse events were observed.

Metoprolol succinate has a beneficial role in HFpEF